Pantheon Vision and Eyedeal Medical enter collaborative agreement to develop bioengineered corneal implant

News
Article

Pantheon Vision’s bioengineered corneal implant aims to tackle issues with the success rate of human donated tissue.

Two scientists conversing in a lab Image credit: AdobeStock/peopleimages.com

Image credit: AdobeStock/peopleimages.com

Pantheon Vision has entered into a collaboration agreement with manufacturer Eyedeal Medical to advance the production and commercialization of Pantheon Vision’s bioengineered corneal implant.

At the beginning of 2025, Pantheon completed its third meeting with the US Food and Drug Administration (FDA) review team, after previously completing 2 pre-submission meetings with the organization. The meetings were for guidance on the initial stages of pre-clinical and clinical work supporting a Premarket Approval (PMA) submission for the company’s bioengineered corneal implants to eliminate corneal blindness.

Guo Guangxu, founder and CEO of Eyedeal Medical, and John Sheets, Jr, PhD, president and CEO of Pantheon Vision commented on the partnership in a press release from Pantheon.

“Pantheon Vision has assembled a world-leading ophthalmic design team whose groundbreaking mindset has enabled the bold development of a revolutionary single-piece polymer artificial cornea for vision restoration,” said Guangxu. “This innovation, upon commercialization, will fundamentally eliminate the need for corneal donations while bringing new hope to global patients requiring corneal transplantation."

“This agreement is a critical step for Pantheon Vision as we advance our mission of developing a bioengineered corneal solution to treat and restore vision for people around the world,” said Sheets Jr “We are grateful for the partnership with Eyedeal Medical and are extremely optimistic that together we can create an innovative solution that will provide meaningful benefits to patients suffering from corneal blindness.”

Human donated tissue has less than a 50% success rate at 5 years, among other issues such as short shelf life and insufficient tissue available. The company aims to tackle these issues with its bioengineered corneal implants.

References:
  1. Pantheon Vision signs collaboration agreement with Eyedeal Medical to develop bioengineered corneal implant. Published March 27, 2025. Accessed March 27, 2025. https://www.businesswire.com/news/home/20250327308058/en/Pantheon-Vision-Signs-Collaboration-Agreement-with-Eyedeal-Medical-to-Develop-Bioengineered-Corneal-Implant

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
Rachelle Lin, OD, MS, FAAO, details her presentation on inherited retinal diseases at CRU 2025.
Setting the stage in LA: Neda Shamie, MD, on the 19th annual Controversies in Modern Eye Care meeting
Jennifer Li, MD, details a talk she gave alongside Melissa Barnett, OD, FAAO, FSLS, FBCLA, at CRU 2025 in Napa, California.
Deb Ristvedt, DO, details a handful of presentations on glaucoma she gave during CRU 2025 in Napa, California.
Cecelia Koetting, OD, FAAO, DipABO, weighs in on patient assessments, staining pattern insights, and diagnostic tips for patients who may have dry eye disease.
Melissa Barnett, OD, FAAO, FSLS, FBCLA, discusses keratoconus management, diagnosis, and other key insights at CRU 2025.
Cecelia Koetting, OD, FAAO, DipABO, details a talk she gave among optometrists and ophthalmologists at CRU 2025.
Alongside Rachelle Lin, OD, MS, FAAO; Nguyễn, MD, MSc, detailed what treatments are currently available for retinal vascular diseases, including neovascular age-related macular degeneration and diabetic retinopathy.
Nora Lee Cothran, OD, FAAO, details a real-world study that found IOP-lowering benefits when switching patients with glaucoma to latanoprostene bunod treatment.
© 2025 MJH Life Sciences

All rights reserved.